Yuki Oda

571 total citations
31 papers, 380 citations indexed

About

Yuki Oda is a scholar working on Surgery, Oncology and Molecular Biology. According to data from OpenAlex, Yuki Oda has authored 31 papers receiving a total of 380 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Surgery, 13 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in Yuki Oda's work include Bladder and Urothelial Cancer Treatments (15 papers), Urinary and Genital Oncology Studies (10 papers) and Multiple Myeloma Research and Treatments (5 papers). Yuki Oda is often cited by papers focused on Bladder and Urothelial Cancer Treatments (15 papers), Urinary and Genital Oncology Studies (10 papers) and Multiple Myeloma Research and Treatments (5 papers). Yuki Oda collaborates with scholars based in Japan and United Kingdom. Yuki Oda's co-authors include Tsuyoshi Yokoi, Tatsuki Fukami, Miki Nakajima, Shingo Takagi, Masataka Takamiya, Yasuhiro Aoki, Tomomi Fujii, Kiyohide Fujimoto, Makito Miyake and Shunta Hori and has published in prestigious journals such as Scientific Reports, Biochemical Pharmacology and Pharmaceutical Research.

In The Last Decade

Yuki Oda

27 papers receiving 374 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yuki Oda Japan 11 218 163 81 67 50 31 380
Feng Cao China 13 200 0.9× 151 0.9× 82 1.0× 62 0.9× 43 0.9× 33 385
Ibone Labiano Spain 7 289 1.3× 108 0.7× 91 1.1× 84 1.3× 65 1.3× 10 493
Huiyue Dong China 14 302 1.4× 158 1.0× 65 0.8× 60 0.9× 83 1.7× 20 485
Xiaofeng Zou China 12 304 1.4× 153 0.9× 56 0.7× 55 0.8× 20 0.4× 42 447
Xiaomei Liu China 10 146 0.7× 60 0.4× 44 0.5× 50 0.7× 42 0.8× 35 328
Yurie Soejima Japan 12 125 0.6× 59 0.4× 82 1.0× 62 0.9× 76 1.5× 33 355
Keqiang Zuo China 12 221 1.0× 149 0.9× 61 0.8× 36 0.5× 26 0.5× 19 423
Weidong Wu China 12 220 1.0× 153 0.9× 43 0.5× 69 1.0× 38 0.8× 46 402
Guang‐Yan Yu China 10 135 0.6× 89 0.5× 83 1.0× 70 1.0× 57 1.1× 32 353

Countries citing papers authored by Yuki Oda

Since Specialization
Citations

This map shows the geographic impact of Yuki Oda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuki Oda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuki Oda more than expected).

Fields of papers citing papers by Yuki Oda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuki Oda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuki Oda. The network helps show where Yuki Oda may publish in the future.

Co-authorship network of co-authors of Yuki Oda

This figure shows the co-authorship network connecting the top 25 collaborators of Yuki Oda. A scholar is included among the top collaborators of Yuki Oda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuki Oda. Yuki Oda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Miyake, Makito, Nobutaka Nishimura, Yuki Oda, et al.. (2025). Real‐World Analysis of the Enfortumab Vedotin‐Ineligible criTeriA Assessment in Treatment‐Naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma. International Journal of Urology. 32(6). 761–763. 1 indexed citations
3.
Shimizu, Takuto, Tomoya Ueda, Kazuki Yamamoto, et al.. (2025). Clinical Utility of Ureteral Optical Coherence Tomography for T Staging of Ureteral Cancer: NOCTURN Study. Journal of Endourology. 39(12). 1276–1284.
4.
5.
Kikuchi, Taku, et al.. (2024). Cytomegalovirus Reactivation during Elotuzumab Therapy in Patients with Multiple Myeloma. Acta Haematologica. 148(1). 1–6. 1 indexed citations
6.
Miyake, Makito, Yuki Oda, Tatsuki Miyamoto, et al.. (2024). Longitudinal assessment of health-related quality of life in Japanese patients with advanced urothelial carcinoma receiving immune check point inhibitors. Scientific Reports. 14(1). 23128–23128.
7.
Kikuchi, Taku, et al.. (2024). Prognostic value of the “dynamic” R2‐ISS in patients with multiple myeloma undergoing anti‐CD38 antibody‐based triplet therapies. Hematological Oncology. 42(5). e3302–e3302. 1 indexed citations
8.
Kikuchi, Taku, Nobuhiro Tsukada, Yuki Oda, et al.. (2024). Cytomegalovirus infection during daratumumab therapy in patients with newly diagnosed multiple myeloma. International Journal of Hematology. 120(1). 91–95. 1 indexed citations
9.
10.
Miyake, Makito, Shunta Hori, Tomomi Fujii, et al.. (2023). Clinical practice of UroVysion® urine test in patients with bladder carcinoma in situ treated with intravesical Bacillus Calmette–Guerin. Japanese Journal of Clinical Oncology. 53(7). 629–632. 1 indexed citations
11.
Kikuchi, Taku, Nobuhiro Tsukada, Yuki Oda, et al.. (2023). Real-world clinical outcomes in patients with multiple myeloma treated with isatuximab after daratumumab treatment. Annals of Hematology. 102(6). 1477–1483. 10 indexed citations
12.
Miyake, Makito, Nobutaka Nishimura, Sayuri Ohnishi, et al.. (2023). Diagnostic and Prognostic Roles of Urine Nectin-2 and Nectin-4 in Human Bladder Cancer. Cancers. 15(9). 2565–2565. 5 indexed citations
13.
Miyake, Makito, Takashi Yoshida, Nobutaka Nishimura, et al.. (2022). A prospective, single-arm trial of fluorescent ureteroscopy-assisted thulium-holmium:YAG dual laser ablation for upper urinary tract cancer: Study protocol of the FLUAM trial. Contemporary Clinical Trials Communications. 26. 100902–100902. 6 indexed citations
14.
Nishimura, Nobutaka, Makito Miyake, Takuto Shimizu, et al.. (2022). First-line pembrolizumab for patients with early relapsing urothelial carcinoma after perioperative chemotherapy: a retrospective analysis of bladder cancer and upper urinary tract cancer. International Journal of Clinical Oncology. 27(11). 1733–1741. 2 indexed citations
15.
Miyake, Makito, Tatsuki Miyamoto, Takuto Shimizu, et al.. (2022). Tumor expression of Nectin-1–4 and its clinical implication in muscle invasive bladder cancer: An intra-patient variability of Nectin-4 expression. Pathology - Research and Practice. 237. 154072–154072. 11 indexed citations
16.
Nitahara‐Kasahara, Yuko, Mutsuki Kuraoka, Yuki Oda, et al.. (2021). Enhanced cell survival and therapeutic benefits of IL-10-expressing multipotent mesenchymal stromal cells for muscular dystrophy. Stem Cell Research & Therapy. 12(1). 105–105. 25 indexed citations
17.
Miyake, Makito, Yasushi Nakai, Nobutaka Nishimura, et al.. (2021). Hexylaminolevulinate‐mediated fluorescent urine cytology with a novel automated detection technology for screening and surveillance of bladder cancer. British Journal of Urology. 128(2). 244–253. 6 indexed citations
18.
Miyake, Makito, Yuki Oda, Nobutaka Nishimura, et al.. (2020). Integrative assessment of clinicopathological parameters and the expression of PD‑L1, PD‑L2 and PD‑1 in tumor cells of retroperitoneal sarcoma. Oncology Letters. 20(5). 1–1. 11 indexed citations
19.
Oda, Yuki, Miki Nakajima, Koichi Tsuneyama, et al.. (2014). Retinoid X receptor α in human liver is regulated by miR-34a. Biochemical Pharmacology. 90(2). 179–187. 42 indexed citations
20.
Oda, Yuki, Miki Nakajima, Masataka Takamiya, et al.. (2012). Aryl hydrocarbon receptor nuclear translocator in human liver is regulated by miR-24. Toxicology and Applied Pharmacology. 260(3). 222–231. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Feng Cao Breakdown of academic impact, for papers by Ibone Labiano Breakdown of academic impact, for papers by Huiyue Dong Breakdown of academic impact, for papers by Xiaofeng Zou Breakdown of academic impact, for papers by Xiaomei Liu Breakdown of academic impact, for papers by Yurie Soejima Breakdown of academic impact, for papers by Keqiang Zuo Breakdown of academic impact, for papers by Weidong Wu Breakdown of academic impact, for papers by Guang‐Yan Yu
Rankless by CCL
2026